Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall...
Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, and colleagues, the third prespecified interim analysis of overall survival in the phase...
Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
In a study reported in a research letter in JAMA Oncology, Storgard et al identified the risk of T-cell malignant neoplasms and any second primary malignant neoplasms...
Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care
The current body of research may inadequately address the intersection of aging, health disparities, and cancer outcomes among older patients...
Combined ICI and VEGF Inhibitor Trials in Cancer: Cardiovascular Eligibility Criteria and Adverse Event Reporting
In a study reported in JACC:CardioOncology, Rankin et al analyzed the degree to which published phase II to IV trials of combination immune checkpoint inhibitor (ICI) and...
Susan Faye Dent: Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
Kelly Hewitt and Laura J. Esserman: Reframing DCIS as an Opportunity for Cancer Prevention
Garth Strohbehn, Allen Lichter, and Mark Ratain: Sotorasib, the Poster Child for Project Optimus
Kevin B. Knopf and Charles L. Bennett: Generic Drug Shortages and Essential Cancer Medicines
Stuart M. Lichtman: All Adult Oncologists Are Geriatric Oncologists
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting Rare, Actionable Alterations in Advanced Non–Small Cell Lung Cancer
Study Finds Need to Improve Knowledge About Palliative Care Among U.S. Adults
The use of palliative care in hospitals in the United States has steadily risen over the past decade, with almost universal access to services in large hospitals and academic medical centers. Despite this increased access and recommendations from ASCO that all patients with advanced cancer receive...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL
The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...
Does Vitamin D Supplementation Improve Prognosis for Patients With Breast Cancer?
A research team has found that sufficient vitamin D levels at the time of diagnosis may be associated with improved outcomes among people with breast cancer. These findings were presented by Yao et al during the 2021 ASCO Annual Meeting (Abstract 10510). These findings are based on Kaiser...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes
A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
